Skip to main content

Advertisement

SpringerLink
Log in

The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis

  • Topic Review
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Background

Mutations in the telomerase reverse transcriptase promoter (TERTp) region have been associated with worse prognosis in some cancers. Meningiomas are the most common type of primary central nervous tumors, and evaluation of the prognostic significance of TERTp mutations across the literature is lacking. The aim of this study was to pool all current evidence to assess for clinical relevance of TERTp mutations in meningioma and survival effect.

Methods

Searches of seven electronic databases from inception to September 2018 were conducted following the appropriate guidelines. Two hundred and twenty seven articles were identified for screening. Hazard ratio (HR) and mean difference (MD) statistics were obtained and pooled utilizing both fixed- and random-effect (RE) models. Meta-regression was utilized to determine potential sources of heterogeneity and statistical influence.

Results

A total of five retrospective observational cohort studies describing 532 meningioma patients satisfied selection criteria. The incidence of TERTp mutations was 8%, and was associated with significantly worse prognosis (HR 3.79; P = 0.005) and significantly shorter overall survival (MD 59.8 months; P = 0.037) by RE modelling. Meningioma grade was not significantly associated with a TERTp mutation effect, however, preliminary meta-regression trends indicated this may be significant once greater statistical power is achieved.

Conclusion

The current evidence indicates the presence of a TERTp mutation in meningioma can be associated with worse prognosis, and shorter overall survival. Routine detection in greater numbers will allow for further validation, as well as delineate the effect across histological grades. By identifying this subgroup of meningioma patients early in management, it may support more frequent follow-up and aggressive management to optimize survival outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-oncology 17(Suppl 4):iv1–iv62. https://doi.org/10.1093/neuonc/nov189

    Article  PubMed  PubMed Central  Google Scholar 

  2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta neuropathologica 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1

    Article  PubMed  Google Scholar 

  3. Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M, Weber DC, Baumert BG, Canyilmaz E, Yalman D, Szutowicz E, Tzuk-Shina T, Mirimanoff RO (2008) Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys 71(5):1388–1393. https://doi.org/10.1016/j.ijrobp.2007.12.020

    Article  PubMed  Google Scholar 

  4. van Alkemade H, de Leau M, Dieleman EM, Kardaun JW, van Os R, Vandertop WP, van Furth WR, Stalpers LJ (2012) Impaired survival and long-term neurological problems in benign meningioma. Neuro-oncology 14(5):658–666. https://doi.org/10.1093/neuonc/nos013

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ehresman JS, Mampre D, Rogers D, Olivi A, Quinones-Hinojosa A, Chaichana KL (2018) Volumetric tumor growth rates of meningiomas involving the intracranial venous sinuses. Acta Neurochir 160(8):1531–1538. https://doi.org/10.1007/s00701-018-3571-3

    Article  PubMed  Google Scholar 

  6. Ehresman JS, Garzon-Muvdi T, Rogers D, Lim M, Gallia GL, Weingart J, Brem H, Bettegowda C, Chaichana KL, and Meningiomas III (2018) The relevance of simpson grade resections in modern neurosurgical treatment of World Health Organization Grade I, II. World Neurosurg 109:e588–e593. https://doi.org/10.1016/j.wneu.2017.10.028

    Article  PubMed  Google Scholar 

  7. Chaichana KL, Pendleton C, Zaidi H, Olivi A, Weingart JD, Gallia GL, Lim M, Brem H, Quinones-Hinojosa A (2013) Seizure control for patients undergoing meningioma surgery. World Neurosurg 79(3–4):515–524. https://doi.org/10.1016/j.wneu.2012.02.051

    Article  PubMed  Google Scholar 

  8. Quinones-Hinojosa A, Kaprealian T, Chaichana KL, Sanai N, Parsa AT, Berger MS, McDermott MW (2009) Pre-operative factors affecting resectability of giant intracranial meningiomas. Can J Neurol Sci 36(5):623–630

    Article  PubMed  Google Scholar 

  9. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961. https://doi.org/10.1126/science.1230062

    Article  PubMed  CAS  Google Scholar 

  10. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959. https://doi.org/10.1126/science.1229259

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Leao R, Apolonio JD, Lee D, Figueiredo A, Tabori U, Castelo-Branco P (2018) Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J Biomed Sci 25(1):22. https://doi.org/10.1186/s12929-018-0422-8

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, Hemminki K, Kumar R (2015) Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J cancer 137(7):1621–1629. https://doi.org/10.1002/ijc.29526

    Article  PubMed  CAS  Google Scholar 

  13. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O’Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499–2508. https://doi.org/10.1056/NEJMoa1407279

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110(15):6021–6026. https://doi.org/10.1073/pnas.1303607110

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Moher D, Liberati A, Tetzlaff J, Althman D (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med 6(7):e1000097

    Article  PubMed  PubMed Central  Google Scholar 

  16. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

    Article  PubMed  PubMed Central  Google Scholar 

  17. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controll Clin Trials 7(3):177–188

    Article  CAS  Google Scholar 

  18. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101

    Article  PubMed  CAS  Google Scholar 

  20. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463

    Article  PubMed  CAS  Google Scholar 

  21. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. https://doi.org/10.1136/bmj.328.7454.1490

    Article  PubMed  Google Scholar 

  22. Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P (2016) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, Ottawa (ON)

    Google Scholar 

  23. Spiegl-Kreinecker S, Lotsch D, Neumayer K, Kastler L, Gojo J, Pirker C, Pichler J, Weis S, Kumar R, Webersinke G, Gruber A, Berger W (2018) TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro-oncology. https://doi.org/10.1093/neuonc/noy104

    Article  PubMed  PubMed Central  Google Scholar 

  24. Peyre M, Gauchotte G, Giry M, Froehlich S, Pallud J, Graillon T, Bielle F, Cazals-Hatem D, Varlet P, Figarella-Branger D, Loiseau H, Kalamarides M (2018) De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. Neuro-oncology 20(8):1113–1121. https://doi.org/10.1093/neuonc/nox231

    Article  PubMed  CAS  Google Scholar 

  25. Biczok A, Kraus T, Suchorska B, Terpolilli NA, Thorsteinsdottir J, Giese A, Tonn JC, Schichor C (2018) TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. J Neuro-oncol 139(3):671–678. https://doi.org/10.1007/s11060-018-2912-7

    Article  CAS  Google Scholar 

  26. Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, Penson T, Krause M, Appold S, Meinhardt M, Pinzer T, Miller JJ, Krex D, Ely HA, Silverman IM, Christiansen J, Schackert G, Wakimoto H, Kirsch M, Brastianos PK, Cahill DP (2017) Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget 8(65):109228–109237. https://doi.org/10.18632/oncotarget.22650

    Article  PubMed  PubMed Central  Google Scholar 

  27. Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, Wang Q, Sulman EP, Adeberg S, Koch A, Okuducu AF, Brehmer S, Schittenhelm J, Becker A, Brokinkel B, Schmidt M, Ull T, Gousias K, Kessler AF, Lamszus K, Debus J, Mawrin C, Kim YJ, Simon M, Ketter R, Paulus W, Aldape KD, Herold-Mende C, von Deimling A (2016) TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv377

    Article  PubMed  Google Scholar 

  28. Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK (2018) DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. https://doi.org/10.1007/s00401-018-1899-7

    Article  PubMed  Google Scholar 

  29. Furtjes G, Kochling M, Peetz-Dienhart S, Wagner A, Hes K, Hasselblatt M, Senner V, Stummer W, Paulus W, Brokinkel B (2016) hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas. J Neuro-oncol 130(1):79–87

    Article  CAS  Google Scholar 

  30. Abedalthagafi MS, Bi WL, Merrill PH, Gibson WJ, Rose MF, Du Z, Francis JM, Du R, Dunn IF, Ligon AH, Beroukhim R, Santagata S (2015) ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet 208(6):345–350. https://doi.org/10.1016/j.cancergen.2015.03.005

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M (2014) High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol (Zurich Switzerland) 24(2):184–189. https://doi.org/10.1111/bpa.12110

    Article  CAS  Google Scholar 

  32. Okuducu AF, Zils U, Michaelis SA, Mawrin C, von Deimling A (2006) Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer 107(6):1365–1372. https://doi.org/10.1002/cncr.22130

    Article  PubMed  CAS  Google Scholar 

  33. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193):2011–2015

    Article  PubMed  CAS  Google Scholar 

  34. Chiba K, Lorbeer FK, Shain AH, McSwiggen DT, Schruf E, Oh A, Ryu J, Darzacq X, Bastian BC, Hockemeyer D (2017) Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science 357(6358):1416–1420. https://doi.org/10.1126/science.aao0535

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Kressner M, Arlt F, Riepl W, Meixensberger J (2018) Prognostic factors of microsurgical treatment of intracranial meningiomas—a multivariate analysis. PLoS ONE 13(10):e0202520. https://doi.org/10.1371/journal.pone.0202520

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Proctor DT, Ramachandran S, Lama S, Sutherland GR (2018) Towards molecular classification of meningioma: evolving treatment and diagnostic paradigms. World Neurosurg 119:366–373. https://doi.org/10.1016/j.wneu.2018.08.019

    Article  PubMed  Google Scholar 

  37. Serakinci N, Mega Tiber P, Orun O (2018) Chromatin modifications of hTERT gene in hTERT-immortalized human mesenchymal stem cells upon exposure to radiation. Eur J Med Genet 61(5):288–293. https://doi.org/10.1016/j.ejmg.2017.12.014

    Article  PubMed  Google Scholar 

  38. Chen W, Shin KH, Kim S, Shon WJ, Kim RH, Park NH, Kang MK (2018) hTERT peptide fragment GV1001 demonstrates radioprotective and antifibrotic effects through suppression of TGFbeta signaling. Int J Mol Med 41(6):3211–3220. https://doi.org/10.3892/ijmm.2018.3566

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Li Y, Pan G, Chen Y, Yang Q, Hao T, Zhao L, Zhao L, Cong Y, Diao A, Yu P (2018) Inhibitor of the human telomerase reverse trancriptase (hTERT) gene promoter induces cell apoptosis via a mitochondrial-dependent pathway. Eur J Med Chem 145:370–378. https://doi.org/10.1016/j.ejmech.2017.12.077

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, 2050, Australia

    Victor M. Lu

  2. Mayo Clinic Neuro-Informatics Laboratory, Mayo Clinic, Rochester, MN, USA

    Anshit Goyal

  3. Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia

    Adrian Lee

  4. Department of Pathology, Mayo Clinic, Jacksonville, FL, USA

    Mark Jentoft

  5. Department of Neurosurgery, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    Alfredo Quinones-Hinojosa & Kaisorn L. Chaichana

Authors
  1. Victor M. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anshit Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adrian Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Jentoft
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alfredo Quinones-Hinojosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kaisorn L. Chaichana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Victor M. Lu or Kaisorn L. Chaichana.

Ethics declarations

Conflict of interest

The authors report no funding sources or conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 154 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, V.M., Goyal, A., Lee, A. et al. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis. J Neurooncol 142, 1–10 (2019). https://doi.org/10.1007/s11060-018-03067-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-018-03067-x

Keywords

Search

Navigation